[Congress] Targeted Radiopharmaceuticals Summit, 8-10 December 2020

[Congress] Targeted Radiopharmaceuticals Summit,

Discover a brand new alliance to serve therapeutic and diagnostic program needs in Discovery, Preclinical, Clinical I/II/III

The development of theranostics requires highly specific expertise and strong collaboration between preclinical and clinical development. Oncodesign and ABX-CRO will present together the prerequisite going into Clinical Phase I and how to evaluate key criteria in preclinical phase.

Register now and take advantage of a 20% discount on your registration thanks to Oncodesign with the code “Onco20

[Talk] It takes 2 to Tango: Path from Preclinical to Clinical Phase I for Imaging and Therapeutic Radiopharmaceuticals
When? Wednesday 9 December at 1:40pm

Come & listen to Dr. Berthet during his LIVE scientific presentation. He will unveil how Oncodesign-ABX joined expertise and our multi-modal pharmaco-imaging & targeted radiotherapy platforms available to our clients to move their theranostic projects faster.

  • Discovery & Preclinical Pharmacology
  • Radiolabeling & Pharmaco-Imaging
  • Systemic Targeted Radiotherapy
  • DMPK, Bioanalysis, Dosimetry
  • Toxicology
  • Radioactive IND/IMPD development
  • Clinical study management I/II/III

Working as a translational team, Oncodesign and ABX-CRO joined know-how from the radiolabeling to late stage development provides optimum research solutions for diagnostic imaging and targeted radiotherapy.

[Panel discussion] Development of theranostics from Preclinical to Clinical Phase I
When? Wednesday 9 December at 2:20pm
[Virtual booth] You can also speak with the team at any time during the conference on Oncodesign/ABX shared virtual booth!

Emilie Soulier, Cyril Berthet, Eftychia Koumarianou and Maik Rossmann will be connected to answer all your questions.

Fix a meeting with Cyril Berthet

I want to know more!

[Webinar] [EN] How do we keep you in the race of COVID-19?

Registrer on line [Webinar] How do we keep you in the race of COVID-19?

Register [Webinar] How do we keep you in the race of COVID-19?

Infectious diseases are caused by pathogenic micro-organisms, such as bacteria, viruses, parasites or fungi; diseases can be transmitted, directly or indirectly, from one person to another. Infectious diseases are caused by pathogenic micro-organisms, such as bacteria, viruses, parasites or fungi; diseases can be transmitted, directly or indirectly, from one person to another.Infectious diseases are caused by pathogenic micro-organisms, such as bacteria, viruses, parasites or fungi; diseases can be transmitted, directly or indirectly, from one person to another. Infectious diseases are caused by pathogenic micro-organisms, such as bacteria, viruses, parasites or fungi; diseases can be transmitted, directly or indirectly, from one person to another.

Three infectious diseases have been ranked among the top ten causes of death worldwide in 2016 by the World Health Organization. These are lower respiratory tract infections (3.0 million deaths), diarrheal diseases (1.4 million deaths) and tuberculosis (1.3 million deaths). 

We are currently facing a new emerging infectious disease with the global COVID-19 outbreak caused by the SARS-CoV-2 virus. Both public research and pharmaceutical industry have been mobilized to find ways to speed up the launch of prophylactic or therapeutic solutions. Faced with this fast-paced demand from the pharmaceutical industry, the CROs are coming together to respond quickly and ingeniously to this unprecedented health crisis.

Come and listen to Innovative Providers' solutions (Oncodesign, Cynbiose, ERBC & PharmaLex a.r.c.).

We will unveil our continuum of specialties to unlock the scientific padlocks linked to Covid-19.

Key learning objectives

  • Panorama of Emergent & Infectious Disease
  • The ongoing COVID-19 outbreak
  • Challenges to overcome ​to find a solution against Covid-19​
  • Our scientific & smart specialties to keep you in the race

Discover our speakers

I register on line

[Congress] Infectious Diseases Virtual Partnering - 2-4 December 2020

[Congress] Infectious Diseases Virtual Partnering - 2-4 December 2020

Oncodesign is engaged and committed to help finding therapeutic solutions and innovative treatments against pandemic COVID-19 disease.
We offer solutions to evaluate innovative preventive and therapeutic strategies both on COVID-19 infection but also on its associated complications, such as cytokine storm or lung fibrosis in Acute Respiratory Distress Syndrome!

Discover our in vitro and in vivo models:

  • In vitro models: cell and biochemical assays
  • In vivo models: non-human primates and Golden Syrian hamster

Our team will unveil our continuum of specialties to unlock the scientific padlocks linked to COVID-19.

I schedule a meeting with Emily, Nicolas and Christophe!

I want to know more!

[Congress] Microbiome & Probiotics R&D & Business Collaboration Forum: Europe, November 30 – December 1

[Congress] Microbiome & Probiotics R&D & Business Collaboration Forum: Europe, November 30 – December 1

We offer tailor-made strategies to study the vitro/vivo efficacy of your bacterial-based treatments and/or the effect of your therapies on the microbiota. 

Join Dr Sylvie Maubant during the "speed networking" sessions and discover the scientific expertise of Oncodesign implemented to evaluate the interaction between the tumour, the microbiota and the therapies.

We will be connected to give you the answers you need for your project.

Schedule a meeting with Sylvie Maubant

I want to know more!